CymaBay Therapeutics, Inc. announced that Dr. Dennis Kim, the Chief Medical Officer submitted his resignation to CymaBay. In connection with the resignation, CymaBay and Dr. Kim have entered into a Transition Agreement, effective February 20, 2023, wherein Dr. Kim will continue as a CymaBay employee through and including May 17, 2023. The Transition Agreement provides that Dr. Kim will receive all of his current employee benefits (including salary and stock option vesting) through May 17, 2023.

He will not receive any additional payments in connection with his resignation.